The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab [PDF]
Cardiology JournalBACKGROUND: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).
Onur Altınkaya +9 more
doaj +4 more sources
Therapeutics and Clinical Risk Management, 2014 Artur Dziewierz,1 Tomasz Rakowski,1 Dariusz Dudek2 12nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland; 2Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland Abstract ...
Dziewierz A, Rakowski T, Dudek D
doaj +4 more sources
Breaking the Barrier: Unraveling the No‐Reflow Phenomenon in Cardiovascular Medicine [PDF]
Catheterization and Cardiovascular Interventions, Volume 106, Issue 3, Page 1937-1945, September 1, 2025.ABSTRACT The no‐reflow phenomenon is a stubborn and often devastating complication in cardiovascular medicine, where blood flow is restored to an artery, yet the microvasculature remains unresponsive. First identified in 1967, this phenomenon has haunted clinicians and researchers alike, particularly in the context of acute myocardial infarction (AMI).
Stephanie Howes +9 more
wiley +2 more sources
Abciximab in rescue therapy of thromboembolic events during endovascular treatment of cerebral aneurysms: single center experience of 49 cases [PDF]
Frontiers in NeurologyBackgroundThe aim of this study was to assess the safety and effectiveness of abciximab (ReoPro®), a glycoprotein-IIb/IIIa receptor antagonist, in the management of thromboembolic complications during endovascular treatment of intracranial aneurysms ...
Lukas Lenhart +7 more
doaj +2 more sources
Modeling Versus Balancing Approaches to Addressing Instrumental Variables in Weighting: A Comparison of the Outcome‐Adaptive Lasso, Stable Balancing Weighting, and Stable Confounder Selection [PDF]
Pharmacoepidemiology and Drug Safety, Volume 34, Issue 7, July 2025.ABSTRACT Background Variable selection is essential for propensity score (PS)‐weighted estimators. Recent work shows that including instrumental variables (IVs), associated with only treatment but not with the outcome, can impact both the bias and precision of the PS‐weighted estimators.
Byeong Yeob Choi, M. Alan Brookhart
wiley +2 more sources
Diagnosis and Management of Hypersensitivity to Antiplatelet Drugs: EAACI Position Paper [PDF]
Allergy, Volume 80, Issue 11, Page 2973-2987, November 2025.ABSTRACT Antiplatelet drug (APD) therapy is the cornerstone for the prevention of atherosclerotic cardiovascular disease. The main APDs are aspirin and thienopyridines, particularly clopidogrel. These drugs may induce hypersensitivity reactions (HSRs).
Gabriele Cortellini +10 more
wiley +2 more sources
Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s) [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023 Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000–100 000 platelets/
Sem A. O. F. Rikken +4 more
doaj +2 more sources
Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
Vascular Health and Risk Management, 2010 Jennifer Vergara-Jimenez, Pierluigi TricociDepartment of Medicine-Cardiology, Duke Clinical Research Institute, Durham, North Carolina, USAAbstract: Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients ...
Jennifer Vergara-Jimenez +1 more
doaj +3 more sources
Early recovery of microvascular perfusion induced by t-PA in combination with abciximab or eptifibatide during postischemic reperfusion [PDF]
, 2002 BACKGROUND: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or eptifibatide (Integrilin) alone or in combination with ...
Bertuglia, Silva, Giusti, Andrea
core +4 more sources
Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration [PDF]
Trials, 2009 Background Administration of abciximab during primary percutaneous coronary intervention is an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial infarction.
Gu Youlan L +6 more
doaj +2 more sources